Literature DB >> 21302868

Treatment of acute migraine headache.

Benjamin Gilmore1, Magdalena Michael.   

Abstract

Migraine headache is a common and potentially debilitating disorder often treated by family physicians. Before diagnosing migraine, serious intracranial pathology must be ruled out. Treating acute migraine is challenging because of substantial rates of nonresponse to medications and difficulty in predicting individual response to a specific agent or dose. Data comparing different drug classes are relatively scarce. Abortive therapy should be used as early as possible after the onset of symptoms. Effective first-line therapies for mild to moderate migraine are nonprescription nonsteroidal anti-inflammatory drugs and combination analgesics containing acetaminophen, aspirin, and caffeine. Triptans are first-line therapies for moderate to severe migraine, or mild to moderate migraine that has not responded to adequate doses of simple analgesics. Triptans should be avoided in patients with vascular disease, uncontrolled hypertension, or hemiplegic migraine. Intravenous antiemetics, with or without intravenous dihydroergotamine, are effective therapies in an emergency department setting. Dexamethasone may be a useful adjunct to standard therapy in preventing short-term headache recurrence. Intranasal lidocaine may also have a role in relief of acute migraine. Isometheptene-containing compounds and intranasal dihydroergotamine are also reasonable therapeutic options. Medications containing opiates or barbiturates should be avoided for acute migraine. During pregnancy, migraine may be treated with acetaminophen or nonsteroidal anti-inflammatory drugs (prior to third trimester), or opiates in refractory cases. Acetaminophen, ibuprofen, intranasal sumatriptan, and intranasal zolmitriptan seem to be effective in children and adolescents, although data in these age groups are limited.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21302868

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  39 in total

1.  Comparison of parenteral treatments of acute primary headache in a large academic emergency department cohort.

Authors:  Lucas H McCarthy; Robert P Cowan
Journal:  Cephalalgia       Date:  2014-11-03       Impact factor: 6.292

Review 2.  Serotonin and blood pressure regulation.

Authors:  Stephanie W Watts; Shaun F Morrison; Robert Patrick Davis; Susan M Barman
Journal:  Pharmacol Rev       Date:  2012-03-08       Impact factor: 25.468

3.  A Preliminary Study on the Effects of Self-Reported Dietary Caffeine on Pain Experience and Postoperative Analgesia.

Authors:  Nirmani P Karunathilake; Reginald F Frye; Mary F Stavropoulos; Mary A Herman; Barbara A Hastie
Journal:  J Caffeine Res       Date:  2012-12

Review 4.  Eletriptan in the management of acute migraine: an update on the evidence for efficacy, safety, and consistent response.

Authors:  Matilde Capi; Martina Curto; Luana Lionetto; Fernando de Andrés; Giovanna Gentile; Andrea Negro; Paolo Martelletti
Journal:  Ther Adv Neurol Disord       Date:  2016-06-03       Impact factor: 6.570

5.  Comparative Efficacy of Oral Calcitonin-Gene-Related Peptide Antagonists for the Treatment of Acute Migraine: Updated Meta-analysis.

Authors:  Jae-Hwan Kwak; In-Hwan Baek; Dong Kyoung Ha; Min Ji Kim; Nayoung Han
Journal:  Clin Drug Investig       Date:  2021-01-11       Impact factor: 2.859

6.  Case Study of Fatal Stroke Following Intranasal Lidocaine.

Authors:  Daniel L Moellentin; Dale Stewart; James Barbour
Journal:  Hosp Pharm       Date:  2016-09

7.  Simvastatin and vitamin D for migraine prevention: A randomized, controlled trial.

Authors:  Catherine Buettner; Rony-Reuven Nir; Suzanne M Bertisch; Carolyn Bernstein; Aaron Schain; Murray A Mittleman; Rami Burstein
Journal:  Ann Neurol       Date:  2015-11-13       Impact factor: 10.422

Review 8.  Managing Migraine During Pregnancy and Lactation.

Authors:  Rebecca Erwin Wells; Dana P Turner; Michelle Lee; Laura Bishop; Lauren Strauss
Journal:  Curr Neurol Neurosci Rep       Date:  2016-04       Impact factor: 5.081

9.  Unmet Needs in Japanese Patients Who Report Insufficient Efficacy with Triptans for Acute Treatment of Migraine: Retrospective Analysis of Real-World Data.

Authors:  Koichi Hirata; Kaname Ueda; Mika Komori; Wenyu Ye; Yongin Kim; Sarah Cotton; James Jackson; Tamas Treuer
Journal:  Pain Ther       Date:  2020-12-11

10.  Symptomatic or prophylactic treatment of weekend migraine: an open-label, nonrandomized, comparison study of frovatriptan versus naproxen sodium versus no therapy.

Authors:  Mario Guidotti; Caterina Barrilà; Serena Leva; Claudio De Piazza; Stefano Omboni
Journal:  Neuropsychiatr Dis Treat       Date:  2013-01-16       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.